RATIONALE: Allergen immunotherapy (AIT) treatment for allergic rhinitis and asthma is used by 2.6 million Americans annually. Clinical and sterility testing studies identify no risk of contamination or infection from extracts prepared using recommended aseptic techniques. Regulatory changes to extract preparation are under consideration. Social media can be used to investigate rare adverse effects not captured by traditional studies. We investigated large social media databases for suggestion of AIT infection risk.
Treato Ltd, Or Yehuda, Israel. RATIONALE: Allergen immunotherapy (AIT) treatment for allergic rhinitis and asthma is used by 2.6 million Americans annually. Clinical and sterility testing studies identify no risk of contamination or infection from extracts prepared using recommended aseptic techniques. Regulatory changes to extract preparation are under consideration. Social media can be used to investigate rare adverse effects not captured by traditional studies. We investigated large social media databases for suggestion of AIT infection risk.
METHODS:
We analyzed USA-restricted data from over 10 common text-based social media platforms including Facebook, Twitter and Reddit between 2012-2016. We employed natural language processing (NLP) to identify posts related to AIT, or influenza vaccination, a comparator procedure with a sterile pharmaceutical. NLP was followed by manual review to identify posts suggesting skin and soft tissue infections (SSTI) associated with either AIT or influenza vaccination. SSTI frequencies with 95% confidence intervals (CI) were compared. RESULTS: We identified 25,126 AIT related posts, which were matched by social media platform to 25,126 influenza vaccination related posts. NLP identified 4,088 AIT posts that required manual review, with 6 posts (0.02%, 95% CI 0.018, 0.022) indicative of possible AIT related SSTI. NLP identified 2,689 influenza posts that required manual review, with 7 posts (0.03%, 95% CI 0.028, 0.032) indicative possible influenza vaccination related SSTI. CONCLUSIONS: Social media data suggest that SSTI from AIT and influenza vaccination are equally rare events. Given that AIT's SSTI risk appears comparable to the risk using a sterile pharmaceutical based on social media data, current aseptic technique procedures seem safe. The group 5 allergen of Blomia tropicalis, Blo t 5, is considered the dominant major allergen. Blo t 5 is recognized by IgE up to 98% of mite-allergic and/or asthmatic patients in tropical regions. The aim of this study is to evaluate the performance of Component Resolved Diagnosis (CRD) in patients with moderate-severe allergic rhinitis. METHODS: We selected 20 non-consecutive patients highly sensitized to B. tropicalis with persistent moderate to severe allergic rhinitis according to the ARIA Guidelines. Skin prick test (SPT) with standardized crude extracts of B. tropicalis were performed followed by immediate reading. Serum blood samples were obtained from all participating subjects. Total IgE, specific IgE to B. tropicalis, and semi-quantitative InmunoCAP ISAC was performed in all 20 serum samples. RESULTS: All 20 subjects (11 females, 11 to 45 y.o.) showed a positive SPT to B. tropicalis. Total IgE (UI/mL) ranged from 20.02 to 2581, specific IgE to B. tropicalis (crude extract) was present in all 20 sera, ranging from 0,35 to >100 kU/L (mean value: 19.36 kU/L). Measurements of specific IgE to Blo t5 detected values ranged from 0.1 to 96 ISU-E (mean value: 10.5 ISU-E). Interestingly, specific IgE to Blo t5 (> _0.3 ISU-E) was not detected in the majority (55%) of the serum samples. CONCLUSIONS: Current CRD could not identify the majority of patients with moderate to severe allergic rhinitis and confirmed sensitization to the crude extract of Blomia tropicalis. Additional allergen components are promptly warranted to achieve a precise diagnosis in specific populations. 
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RATIONALE:
The frecuency of systemic reactions to hymenoptera venom immunotherapy (VIT) varies depending on the studies, ranging from 8 to 20%. They have been associated to several risk factors, mainly: the extract administrated, an accelerated build-up phase and mastocytosis. ACE-inhibitors and betablockers are no longer considered as independent risk factors of adverse reactions. Our aim was to assess the safety and efficacy of the rush build-up phase regimen used in our Center (day 1, with the vial at its highest concentration: 5-10-20-20mcg; day 2: 50-50 mcg; day 5: 50-50mcg; day 12: 50-50mcg; followed by a 100 mcg dose each month). METHODS: We completed a registry of all the patients who were receiving VIT in our Center at the moment of submission, using the aforementioned regimen, comprising a total of 58 patients. We took into account the following data: age, gender, concomitant beta-blocker or ACEi therapy, other comorbidities, REMA score (for prediction of mast cell clonality), baseline level of tryptase, mastocytosis, the extract administrated, total igE, specific igE to the culprit venom, profession, previous stings and the delay until VIT was iniciated. RESULTS: None of the patients experienced a reaction during the buildup phase. We only observed autolimited local erythema in 27 out of 58 patients. One systemic reaction (IV grade Mueller's Scale) was detected during the maintenance phase, in a patient diagnosed with mastocytosis. CONCLUSIONS: The regimen used in our Center is safe and it does not increase the risk of reactions during the build-up phase, considering traditional risk factors associated to systemic reactions.
